Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial-March 2024-www.financetom.com

Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial

Mar 13, 2024 4:35 AM

March 13 (Reuters) - Ionis Pharmaceuticals ( IONS ) said

on Wednesday that its experimental drug to treat a type of fatty

liver disease met the primary goal of a mid-stage trial.

Previous page： Supreme Court upholds IBC provisions on personal insolvency Next page： Dhanuka Agritech Q4 net profit up 24.71%

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Supreme Court upholds IBC provisions on personal insolvency

May 21, 2021

The Supreme Court has dismissed a plea by various promoter guarantors against lenders launching insolvency proceedings against them. The apex court has upheld the right of bankers to pursue insolvency proceedings against guarantors of companies facing insolvency resolution.

Dhanuka Agritech Q4 net profit up 24.71%

May 21, 2021

Net income rose on a consolidated basis by 20.34 percent to Rs 284.30 crore in the fourth quarter of 2020-21 fiscal from Rs 236.24 crore in the same quarter previous financial year.

Warburg Pincus and PremjiInvest-Backed MedPlus Picks I-Bankers For Rs 2,000-Crore IPO; First By A Retail Pharmacy Chain

May 21, 2021

MedPlus is an omni-channel retailer with over 1800 stores serving over 3 lakh customers daily according to its website. It also operates online store MedPlusMart, lab testing centres MedPlus Pathlabs and surgical equipment distribution business RiteCure

Hindalco Industries Q4 PAT zooms about 3-folds to Rs 1,928 cr

May 21, 2021

Commenting on the results, Satish Pai, Managing Director, Hindalco Industries Ltd, said, this past year, with all its volatility and uncertainty, has underscored Hindalco’s resilience and ability to deal with challenges.